Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725979 | 0.85 | ADORA3 (0.50) | ADORA3SGMS2LMNAHTTSMN1; SMN2 | |
| SCHEMBL12646990 | 0.83 | KDM4E (0.42) | ADORA3LMNAHTTSMN1; SMN2CHRNB2 | |
| SCHEMBL1643985 | 0.82 | NR1H4 (0.47) | LMNAHTTHPGDRXRARXRB | |
| SCHEMBL12726014 | 0.80 | PTGER1 (0.43) | LMNAHPGDRXRARXRBRXRG | |
| SCHEMBL1636903 | 0.79 | GRM5 (0.40) | SGMS2HTTPTGER1L3MBTL1KDM4E | |
| SCHEMBL1639353 | 0.79 | SCN9A (0.47) | RXRARXRBRXRGPTGER1L3MBTL1 | |
| SCHEMBL1637994 | 0.76 | PTGER1 (0.40) | HPGDRXRARXRBRXRGPTGER1 | |
| SCHEMBL8797209 | 0.76 | PTGER1 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4RXRA | |
| SCHEMBL1315389 | 0.75 | PTGER1 (0.49) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27864148 | 0.74 | MAOB (0.49) | LMNAHTTSMN1; SMN2PTGER1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541521-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541521-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493933-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| CN-102597015-A | Catalyst compounds and use thereof | EXXONMOBIL CHEM PATENTS INC | 2012-07-18 | — | — | CN | disclosed |
| WO-2011056424-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098427-A1 | Catalyst Compounds And Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098427-A1 | Catalyst Compounds And Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098427-A1 | Catalyst Compounds And Use Thereof | THEM6, OPRM1, NOTUM | ADORA3 2402/4885SGMS2 808/4885LMNA 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.